Regulatory PathRegulatory requirements compared

Active substance

Cycloserine

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
SEROMYCIN250MGcapsule · oralSANALUZPrescription29 Jun 1964

UK MHRA United Kingdom — marketing authorisations

ProductAuthorisationHolderLegal status
CYCLOSERINE 250MG HARD CAPSULESPL 45043/0109NEON HEALTHCARE LIMITEDPOM

WHO WHO Model List of Essential Medicines (2025)

  • 6.2.5. Antituberculosis medicines · core
    Multi-drug resistant Mycobacterium tuberculosis
    Oral > Solid > dosage form: 250 mg; 125 mg (EMLc)

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.